|Assessment Status||Rapid review complete|
|Indication||For long-term enzyme replacement therapy (ERT) in patients with type1 Gaucher disease.|
|Rapid review commissioned||26/04/2011|
|Rapid review completed||20/06/2011|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.